Muse is commonly used to help with the treatment of Erectile Dysfunction (ED), a condition characterized by the inability to achieve or maintain penile rigidity sufficient for satisfactory sexual activity. This therapeutic domain is relevant for easing symptoms linked to organ-specific functional stress, such as inadequate penile firmness and difficulty sustaining rigidity.

The medication assists with addressing symptom clusters that interfere with daily functioning. This treatment is often utilized in conditions presenting with systemic or localized discomfort, including ED secondary to vascular issues, diabetes, or post-surgical changes. This approach supports the patient in managing functional stability, which contributes to improved comfort and may assist with maintaining functional stability for the patient. For adult males who have experienced non-response or intolerance to standard oral treatments, Muse is considered relevant as a second-line option. This may be part of symptomatic management, offering a pathway to support when systemic options are exhausted.

---

Quick Fact: Relief for Functional Strain
Primary Indication: Erectile Dysfunction (ED)
Symptom Focus: Inadequate penile firmness and loss of rigidity
Use Context: Localized support; Second-line therapy

Regulatory References

1. NIH MedlinePlus Drug Information

Eligibility Scope

Muse is indicated only for adult men aged 18 years and above. Regulatory bodies classify its use as contraindicated and explicitly prohibit its administration to women and children.

Contraindicated Populations

The medicine must not be used by men with a known hypersensitivity to the drug or by those with conditions that predispose to priapism (prolonged erection), such as certain blood disorders (e.g., sickle cell anemia, multiple myeloma, or leukemia). Use is also forbidden in patients with specific abnormal penile anatomy, including Peyronie’s disease, cavernosal fibrosis, or urethral stricture, as well as those with unstable cardiovascular or cerebrovascular conditions that contraindicate sexual activity.

Eligibility-Related Restrictions

The FDA and EMA labels require the use of a condom barrier during sexual intercourse with a female partner who is pregnant or of child-bearing potential. Caution is advised for patients with a history of hypotension or syncope and those with bleeding disorders or on anticoagulant therapy. Safety and effectiveness are not established in the pediatric population.

Connection to the Overall Eligibility Profile

Official eligibility documents strictly limit use to adult men without specific underlying anatomical, hematologic, or cardiovascular contraindications. The framework sets clear boundaries for non-eligibility and imposes restrictions, such as the mandatory requirement for partner protection during intercourse with pregnant women.

Muse (Alprostadil urethral suppository) is subject to specific regulatory constraints regarding its co-administration with other substances. The product's interaction profile is defined primarily by pharmacodynamic effects rather than systemic pharmacokinetic interactions, as its route of administration leads to rapid local action. Official documents state that the co-administration of Muse with any other agent for the treatment of erectile dysfunction is restricted and classified as a contraindicated combination.

Specific interactions concern the risk of additive effects. Use with antihypertensive agents may result in pharmacodynamic reinforcement, increasing the risk of hypotensive symptoms such as dizziness. When used concomitantly with anticoagulant therapy or platelet aggregation inhibitors (e.g., aspirin or warfarin), there is an officially documented increase in the localized risk of urethral bleeding or spotting.

The effectiveness of Muse may be diminished by pharmacodynamic antagonism. Substances classified as sympathomimetics (such as decongestants or appetite suppressants) may reduce the local vasodilatory effect of Alprostadil. Regarding non-medicinal substances, official sources indicate that alcohol consumption may decrease the overall effectiveness of the medication. A population-specific consideration notes that the risk of hypotensive symptoms may be heightened when vasoactive medications are co-administered in the elderly population.

Direct Activation of Prostanoid Receptors

The mechanism is initiated by Alprostadil acting as an agonist on specific EP2 and EP4 receptors found on local smooth muscle cells and blood vessels. This direct, targeted binding starts the molecular cascade responsible for modulating peripheral vascular tone and is the first step in the modulation of local smooth muscle tone.

Initiating the cAMP Signaling Cascade

Receptor activation engages the cyclic AMP (cAMP) pathway by stimulating Adenylyl Cyclase, which leads to an increase in intracellular cAMP levels. This second messenger system is responsible for lowering the concentration of cytosolic calcium (Ca^2+), which is the biochemical step that regulates the subsequent relaxation of smooth muscle.

Modulating Local Hemodynamics

The resulting relaxation of both the cavernosal arteries and the internal trabecular tissue leads to a dual physiological effect. It causes significant local vasodilation and tissue expansion, enabling increased arterial blood inflow and simultaneously facilitating the physical veno-occlusion mechanism, which facilitates the trapping of blood volume locally.

How Muse is Used: Official Administration Guidelines

Muse is officially administered via the transurethral (intraurethral) route as a medicated micro-suppository system, which delivers the medication directly to the urethral lining for localized absorption. The dosing regimen is not scheduled but is used as needed to achieve an erection, with a strict limitation of no more than two doses in a 24-hour period. Available strengths for titration range from 125 mcg to 1000 mcg.

The initiation of therapy and the dose adjustment must occur under the supervision of a physician, typically starting at the 125 mcg or 250 mcg strength. To ensure proper function, the user must urinate immediately prior to administration to moisten the urethra, a step essential for the pellet's dissolution.

The administration protocol requires specific procedural steps. The penis must be stretched upward to its full length during the insertion of the applicator. After the pellet is released, the penis should be rolled gently for about 10 seconds to distribute the active ingredient. The system is timed, with the expected effect developing within 5 to 10 minutes and lasting approximately 30 to 60 minutes. Use is not approved for pediatric patients. This structured, localized protocol is designed to ensure standardized delivery.

Research Evidence / Overview of Studies for Muse (Alprostadil)

Clinical Evidence for Erectile Dysfunction (ED)

The core research for transurethral Alprostadil was conducted through randomized, placebo-controlled trials (RCTs). These studies were used in research exploring how functional ability changed over defined time intervals. These trials were supplemented by subsequent open-label studies and observational research that was applied in studies examining patient-reported experiences in daily-life functioning.

Research examined outcomes reflecting daily functioning, specifically monitoring the ability to achieve an erection rated sufficient for sexual intercourse in both clinical and home settings. Studies explored whether this outcome was achieved. Findings describe patterns observed in the studies, and the research reported that the outcome was observed more frequently in the groups receiving the active compound compared to the placebo group. Research describes patterns measured during the study period, and individual responses were observed to vary.

Long-Term Data and Follow-Up Studies

The follow-up durations for the primary RCTs were generally limited to a few months after the initial dose-finding period. This means that short-term symptom patterns were the primary focus, and long-term effects are not fully established by the core body of controlled evidence. Evidence derived from settings with varying symptom burdens includes open-label observational extension studies that tracked patients over extended periods. There is limited information for long-term outcomes regarding the maintenance or durability of the functional response.

Evidence Strength, Key Limitations, and Research Uncertainty

The initial evidence was derived from studies categorized by regulators and scientific bodies, including placebo-controlled RCTs. However, evidence quality varies across studies, particularly when moving to long-term or comparative research. A significant limitation is that the results apply only to the populations studied: patients who successfully completed the initial in-clinic dose titration period and could tolerate the medication. Comparative evidence is lacking; specifically, large-scale, head-to-head RCTs comparing transurethral Alprostadil against current first-line oral treatments for ED are generally not available in the public record. Studies help show what has been observed so far, but findings describe group patterns, not personal outcomes.

Common questions about Muse (FAQ)

Q: Does using Muse have any potential impact on a female partner during intercourse?

Official product information states that Muse does not offer protection against sexually transmitted infections (STIs), including HIV, and is not a form of birth control. If the female partner is pregnant or of child-bearing potential, a reliable barrier method, such as a condom, is required in this circumstance according to regulatory information.

Q: Is it possible to have minor spotting or bleeding after using Muse?

Yes, minor bleeding or spotting from the urethra is a very common effect reported in clinical studies. This is typically minor and may result from the insertion process itself. If bleeding is heavy or continues, seek the guidance of a healthcare professional.

Q: Does Muse provide any protection against sexually transmitted diseases (STDs)?

No, the official product labeling confirms that this medication does not offer any protection against sexually transmitted diseases (STDs), including HIV. Protective measures must be used separately to reduce the risk of transmission.

Q: What are the inactive ingredients in the Muse suppository?

The active ingredient, Alprostadil, is combined with a solid base to form the micro-suppository. This base includes ingredients such as polyethylene glycol and lactose. A complete list of all ingredients is detailed in the official product labeling.

Q: How long after using Muse should sexual intercourse be attempted?

According to patient instructions provided by the manufacturer, sexual intercourse should typically be attempted within 10 to 30 minutes after the suppository has been administered. This timeframe is based on when the medication's expected effect begins.

Q: What should I do if the erection lasts longer than the expected timeframe?

Immediate medical attention is necessary if an erection lasts four hours or longer. This is classified as priapism, which is a serious adverse reaction. Prompt treatment is required to prevent potential permanent tissue damage.

Q: Is the use of Muse affected by drinking alcohol?

Official information suggests that alcohol consumption may decrease the medication's overall effectiveness and may also increase the risk of side effects such as dizziness or low blood pressure. Consult a healthcare provider regarding alcohol use while on this medication.

Q: Does the application of Muse require a special technique or is it straightforward?

The transurethral administration involves specific procedural steps to ensure proper delivery of the medication. This protocol includes preparing the penis, inserting the applicator, and ensuring the pellet is released and distributed.

Q: What are the possible signs of an allergic reaction to Muse?

Signs suggestive of a serious allergic reaction, which is rare, necessitate seeking immediate medical care. These signs may include a rash, swelling (especially of the face, tongue, or throat), severe dizziness, or difficulty breathing.

Q: Does Muse have any systemic effects on the rest of the body, like on blood pressure?

Yes. The medication is primarily localized, but its vasodilatory action (widening of blood vessels) can lead to systemic effects. These effects can include a drop in blood pressure (hypotension) and symptoms such as dizziness or fainting.

Q: Why must the applicator be inspected after use to ensure the pellet was released?

Patient instructions require inspecting the applicator after use to confirm that the suppository pellet was completely released into the urethra. If the pellet remains visible, the medication has not been properly administered.

Q: Can a headache be a side effect when using Muse?

Yes, regulatory documents list headache as a common side effect of the medication. If headaches are severe or persistent, consult a healthcare professional.

Q: Is there any research on the effectiveness of Muse in older men?

The clinical studies used for regulatory approval included older patients, and effectiveness was observed in the overall study population. However, official safety notes advise caution in older patients when they also use other vasoactive medications.

Q: Is a follow-up appointment needed when starting treatment with Muse?

The initiation of therapy and any dose adjustments must occur under the supervision of a physician. This process typically requires follow-up with a healthcare professional to monitor the response to the medication and ensure appropriate use.

Q: How quickly can I expect to see the effects of Muse after insertion?

Official product information indicates that the expected therapeutic effects of the medication usually begin quickly, in approximately 5 to 10 minutes after administration.

Q: Is it normal to feel a warming or burning sensation after using Muse?

Yes, a warming or burning feeling or pain in the urethra is reported as a very common local side effect in clinical studies. This is a known reaction to the medication.

Q: Can Muse be used by men who have certain pre-existing heart conditions?

Regulatory labeling indicates that the medication should not be used by men for whom sexual activity itself is inadvisable due to unstable cardiovascular or cerebrovascular conditions. Consult your doctor to assess your specific heart condition.

Q: Is it safe to use Muse if I am also taking medication for high blood pressure?

The co-administration of Muse with antihypertensive agents (blood pressure medications) may lead to an increased risk of hypotensive symptoms (low blood pressure), such as dizziness. This combination should be reviewed by a prescribing physician.

Q: Are there any common over-the-counter supplements that interact with Muse?

Regulatory documents flag interactions primarily with drugs that affect blood pressure or increase the risk of bleeding, such as anticoagulants and sympathomimetics. Always inform your doctor about any supplements or over-the-counter products you are using.

Q: Can Muse be used if I have a condition like Peyronie’s disease?

No, official prescribing information lists Peyronie’s disease as a contraindication. The medication is contraindicated (should not be used) in patients with abnormal penile anatomy, including severe penile curvature.

Q: How does the mechanism of Muse differ from oral ED pills like Viagra or Cialis?

Muse uses a transurethral delivery system to administer Alprostadil, which is a Prostaglandin E1 analogue that works locally. This drug is in a different pharmacological class than oral medications like Viagra or Cialis. Muse is contraindicated for use with any other treatment for erectile dysfunction.

Q: Can the effectiveness of Muse decrease over time with continued use?

Long-term data regarding the durability of the functional response are limited. However, the overall effectiveness and safety profile continue to be monitored over extended periods in observational extension studies.

Q: What happens to the suppository pellet after it is inserted into the urethra?

The small pellet dissolves rapidly once it contacts the moisture inside the urethra. As it dissolves, the active ingredient, Alprostadil, is absorbed into the surrounding tissues to begin its therapeutic action.

Q: What types of men typically find Muse to be an effective treatment?

Clinical studies observed effectiveness in patients who achieved an erection sufficient for sexual intercourse during the initial in-clinic dose assessment period. Results apply only to populations who successfully tolerated and responded to the medication in the study setting.

Q: Can using Muse cause dizziness or lightheadedness, and why?

Yes, dizziness or lightheadedness is listed as a common side effect. This is related to the drug's vasodilatory action, which can potentially lead to a temporary drop in blood pressure (hypotension).

Storage and Disposal Instructions for Muse (alprostadil)

Storage Conditions

Unopened Muse foil pouches require refrigerated storage between 36 F and 46 F (2 C to 8 C) to maintain stability. The product may be stored at controlled room temperature, but for a period not exceeding 14 days, and must not be exposed to temperatures above 86 F (30 C). The medication must be kept in its original foil pouch until immediate use and must be stored out of the reach of children.

Disposal Procedures

Used, single-dose applicators should be placed back into the foil pouch and discarded with household trash. Unused or expired medication should be disposed of through an official drug take-back program. If a take-back program is unavailable, the FDA advises mixing the medicine with an undesirable substance (like coffee grounds) and sealing it in a container before discarding it in the household trash.